Restricted accessResearch articleFirst published online 2016-4-26
Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse
Alzheimer’s disease (AD) is a degenerative and irreversible disorder whose progressiveness is dependent on age. It is histopathologically characterized by the massive accumulation of insoluble forms of tau and amyloid-β (Aβ) asneurofibrillary tangles and neuritic plaques, respectively. Many studies have documented that these two polypeptides suffer several posttranslational modifications employing postmortem tissue sections from brains of patients with AD. In order to elucidate the molecular mechanisms underlying the posttranslational modifications of key players in this disease, including Aβ and tau, several transgenic mouse models have been developed. One of these models is the 3×Tg-AD transgenic mouse, carrying three transgenes encoding APPSWE, S1M146V, and TauP301L proteins. To further characterize this transgenicmouse, we determined the accumulation of fibrillar Aβ as a function of age in relation to the hyperphosphorylation patterns of TauP301L at both its N- and C-terminus in the hippocampal formation by immunofluorescence and confocal microscopy. Moreover, we searched for the expression of activated protein kinases and mediators of inflammation by western blot of wholeprotein extracts from hippocampal tissue sections since 3 to 28 months as well. Our results indicate that the presence of fibrillar Aβ deposits correlates with a significant activation of astrocytes and microglia in subiculum and CA1 regions of hippocampus. Accordingly, we also observed a significant increase in the expression of TNF-α associated to neuritic plaques and glial cells. Importantly, there is an overexpression of the stress activated protein kinases SAPK/JNK and Cdk-5 in pyramidal neurons, which might phosphorylate several residues at the C-terminus of TauP301L. Therefore, the accumulation of Aβ oligomers results in an inflammatory environment that upregulates kinases involved in hyperphosphorylation of TauP301L polypeptide.
Dementia: A public health priority. World Health Organization and Alzheimer’s Disease International (2012) World Health Organization Report, http://www.who.int.
2.
Alzheimer’s Association
(2012) Alzheimer’s disease facts and figures. Alzheimers Dement8, 131–168.
NelsonPT, BraakH, MarkesberyWR (2009) Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol68, 1–14.
5.
TanziRE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med2, a006296.
6.
WeintraubS, WicklundAH, SalmonDP (2012) The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med2, a006171.
7.
BannoK, NakaakiS, SatoJ, ToriiK, NarumotoJ, MiyataJ, HironoN, FurukawaTA, MimuraM, AkechiT (2014) Neural basis of three dimensions of agitated behaviors in patients with Alzheimer disease. Neuropsychiatr Dis Treat10, 339–348.
8.
ThompsonPM, CannonTD, NarrKL, van ErpT, PoutanenVP, HuttunenM (2001) Genetic influences on brain structure. Nat Neurosci4, 1253–1258.
9.
PrestiaA, CaroliA, van der FlierWM, OssenkoppeleR, Van BerckelB, BarkhofF, TeunissenCE, WallAE, CarterSF, SchöllM, ChooIH, NordbergA, ScheltensP, FrisoniGB (2013) Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology11, 1048–1056.
10.
NelsonPT, BraakH, MarkesberyWR (2009) Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol68, 1–14.
TomitaT, IwatsuboT (2013) Structural biology of presenilins and signal peptide peptidases. J Biol Chem288, 14673–14680.
14.
WangaJZ, LiuF (2008) Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol85, 148–175.
15.
GongCX, LiuF, Grundke-IqbalI, IqbalK (2005) Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm112, 813–838.
16.
PevalovaM, FilipcikP, NovakM, AvilaJ, IqbalK (2006) Post-translational modifications of tau protein. Bratisl Lek Listy107, 346–353.
17.
StoothoffWH, JohnsonGVW (2005) Tau phosphorylation: Physiological and pathological consequences. Biochim Biophys Acta1739, 280–297.
18.
GreenbergSM, KooEH, SelkoeDJ, QiuWQ, KosikKS (1994) Secreted beta-Amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc Natl Acad Sci U S A91, 7104–7108.
19.
DrewesG, Lichtenberg-KraagB, DöringF, MandelkowEM, BiernatJ, GorisJ, DoréeM, MandelkowE (1992) Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J11, 2131–2138.
20.
MandelkowEM, DrewesG, BiernatJ, GustkeN, Van LintJ, VandenheedeJR, MandelkowE (1992) Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett21, 315–321.
21.
HangerDP, HughesK, WoodgettJR, BrionJP, AndertonBH (1992) Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett23, 58–62.
22.
VullietR, HalloranSM, BraunRK, SmithAJ, LeeG (1992) Proline-directed phosphorylation of human Tau protein. J Biol Chem5, 22570–22574.
23.
PaudelHK, LewJ, AliZ, WangJH (1993) Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer’s paired helical filaments. J Biol Chem5, 23512–23518.
24.
BaumannK, MandelkowEM, BiernatJ, Piwnica-WormsH, MandelkowE (1993) Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett28, 417–424.
25.
IshiguroK, ShiratsuchiA, SatoS, OmoriA, AriokaM, KobayashiS, UchidaT, ImahoriK (1993) Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett5, 167–172.
26.
ShuklaV, SkuntzS, PantHC (2012) Deregulated Cdk5 activity is involved in inducing Alzheimer’s disease. Arch Med Res43, 655–662.
27.
SteinerB, MandelkowE-M, BiernatJ, GustkeN, MeyerHE, SchmidtB, MieskesG, SölingHD, DrechselD, KirschnerMW, GoedertM, MandelkowE (1990) Phosphorylation of microtubule-associated protein tau: Identification of the site for Ca2 +-calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles. EMBO J9, 3539–3544.
28.
CorreasI, Díaz-NidoJ, AvilaJ (1992) Microtubule-associated protein tau is phosphorylated by protein kinase C on its tubulin binding domain. J Biol Chem5, 15721–15728.
29.
ScottCW, SpreenRC, HermanJL, ChowFP, DavisonMD, YoungJ, CaputoCB (1993) Phosphorylation of recombinant tau by cAMP-dependent protein kinase. Identification of phosphorylation sites and effect on microtubule assembly. J Biol Chem15, 1166–1173.
30.
Morishima-KawashimaM, HasegawaM, TakioK, SuzukiM, YoshidaH, TitaniK, IharaY (1995) Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem13, 823–829.
31.
WegielJ, WisniewskiHM (1990) The complex of microglial cells and Amyloid star in three-dimensional reconstruction. Acta Neuropathol81, 116–124.
32.
BolmontT, HaissF, EickeD, RaddeR, MathisCA, KlunkWE, KohsakaS, JuckerM, CalhounME (2008) Dynamics of the microglial/Amyloid interaction indicate a role in plaque maintenance. J Neurosci28, 4283–4292.
33.
AkamaKT, Van EldikLJ (2000)
β-Amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β- and tumor necrosis factor-α (TNFα)-dependent, and involves a TNFa receptor-associated factor and NFκB-inducing kinase-dependent signaling mechanism. J Biol Chem275, 7918–7924.
34.
SastreM, KlockgetherT, HenekaMT (2010) Contribution of inflammatory processes to Alzheimer’s disease: Molecular mechanisms. Int J Dev Neurosci24, 167–176.
35.
CarreroI, GonzaloMR, MartinB, Sanz-AnquelaJM, Arévalo-SerranoJ, Gonzalo-RuizA (2012) Oligomers of β-Amyloid protein (Aβ1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1β, tumor necrosis factor-a and a nuclear factor κ-B mechanism in the rat brain. Exp Neurol236, 215–227.
36.
MedeirosR, LaFerlaFM (2013) Astrocytes: Conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol239, 133–138.
37.
RossnerS, Lange-DohnaC, ZeitschelU, Perez-PoloJR (2005) Alzheimer’s disease β-secretase BACE1 is not a neuron-specific enzyme. J Neurochem92, 226–324.
WalterS, LetiembreM, LiuY, HeineH, PenkeB, HaoW, BodeB, ManiettaN, WalterJ, Schulz-SchufferW, FassbenderK (2007) Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem20, 947–956.
40.
JinJJ, KimHD, MaxwellJA, LiL, FukuchiK (2008) Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer’s disease. J Neuroinflammation5, 23.
41.
BsibsiM, BajramovicJJ, Van DuijvenvoordenE, PersoonC, RavidR, Van NoortJM, VogtMHJ (2007) Identification of soluble CD14 as an endogenous agonist for Toll-like receptor 2 on human astrocytes by genome-scale functional screening of glial cell derived proteins. Glia55, 473–482.
42.
SongM, JinJ, LimJE, KouJ, PattanayakA, RehmanJA, KimHD, TaharaK, LalondeR, FukuchiK (2011) TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer’s disease. J Neuroinflammation8, 92.
43.
LiuS, LiuY, HaoW, WolfL, KiliaanAJ, PenkeB, RübeCE, WalterJ, HenekaMT, HartmannT, MengerMD, FassbenderK (2012) TLR2 is a primary receptor for Alzheimer’s Amyloidβ peptide to trigger neuroinflammatory activation. J Immunol188, 1098–1107.
44.
OjalaJO, AlafuzoffI, HerukkaSK, van GroenT, TanilaH, PirttiläT (2009) Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients. Neurobiol Aging30, 198–209.
45.
OjalaJO, SutinenEM, SalminenA, PirttiläT (2008) Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells. J Neuroimmunol205, 86–95.
46.
SutinenEM, PirttiläT, AndersonG, SalminenA, OjalaJO (2012) Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated Amyloid-β production in human neuron-like cells. J Neuroinflammation9, 199.
47.
StanteM, MinopoliG, PassaroF, RaiaM, VecchioLD, RussoT (2009) Fe65 is required for Tip60-directed histone H4 acetylation at DNA strand breaks. Proc Natl Acad Sci U S A106, 5093–5098.
48.
BillingsleyML, KincaidRL (1997) Regulated phosphorylation and dephosphorylation of Tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J323, 577–591.
49.
BuéeL, BussiereT, Buée-ScherrerV, DelacourteA, HofPR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev33, 95–130.
50.
MenaR, WischikCM, NovakM, MilsteinC, CuelloAC (1991) A progressive deposition of paired helical filaments (PHF) in the brain characterizes the evolution of dementia in Alzheimer’s Disease. An immunocytochemical study with a monoclonal antibody against the PHF core. J Neuropathol Exp Neurol50, 474–490.
51.
MenaR, EdwardsPC, HarringtonCR, Mukaetova-LadinskaEB, WischikCM (1996) Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol91, 633–641.
52.
Garcia-SierraF, Mondragon-RodriguezS, Basurto-IslasG (2008) Truncation of tau protein and its pathological significance in Alzheimer’s disease. J Alzheimers Dis14, 401–409.
53.
Luna-MuñozJ, Chávez-MacíasL, García-SierraF, MenaR (2007) Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease. J Alzheimers Dis12, 365–375.
54.
WalkerLC, DiamondMI, DuffKE, HymanBT (2013) Mechanism of protein seeding in neurodegenerative diseases. JAMA Neurol70, 304–310.
55.
LeeJE, HanPL (2013) An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp Neurobiol22, 84–95.
56.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Ad and synaptic dysfunction. Neuron39, 409–421.
57.
OddoS, CaccamoA, KitazawaM, TsengBP, LaFerlaFM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging24, 1063–1070.
58.
ApeltJ, SchliebsR (2001) Beta-Amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res894, 21–27.
59.
Orta-SalazarE, Aguilar-VázquezA, Martínez-CoriaH, Luquín-De AndaS, Rivera-CervantesM, Beas-ZarateC, Feria-VelascoA, Díaz-CintraS (2014) REST/NRSF-induced changes of ChAT protein expression in the neocortex and hippocampus of the 3xTg-AD mouse model for Alzheimer’s disease. Life Sci116, 83–89.
60.
Coronas-SámanoG, PortilloW, Beltrén CamposV, Medina-AguirreGI, ParedesRG, Diaz-CintraS (2014) Deficits inodor-guided behaviors in the transgenic 3xTg-AD female mouse model of Alzheimer’s disease. Brain Res1572, 18–25.
61.
GhoshD, LeVaultKR, BarnettAJ, BrewerGJ (2012) A reversible early oxidized redox state that precedes macromolecular ROS damage in aging nontransgenic and 3xTg-AD mouse neurons. J Neurosci32, 5821–5832.
62.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
63.
OddoS, CaccamoA, GreenKN, LiangK, TranL, ChenY, LeslieFM, LaFerlaFM (2005) Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer’s disease. Proc Natl Acad Sci U S A102, 3046–3051.
64.
WischikCM, EdwardsPC, LaiRYK, RothM, HarringtonCR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A93, 11213–11218.
65.
MenaR, EdwardsPC, HarringtonCR, Mukaetova-LadinskaEB, WischikCM (1996) Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer’s disease. Acta Neuropathol91, 633–641.
66.
WeaverCL, EspinosaM, KressY, DaviesP (2000) Conformational change as one of the earliest alterations of tau in Alzheimer’s disease. Neurobiol Aging21, 719–727.
67.
JichaGA, LaneE, VincentI, OtvosL, HoffmanR, DaviesP (1997) A conformational- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer’s disease. J Neurochem69, 2087–2095.
68.
JichaGA, BowserR, KazamIG, DaviesP (1997) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res48, 128–132.
69.
PaxinosG, FranklinKBJ (2008) Paxinos and Franklin’s the mouse brain in stereotaxic coordinates, sixth edition. Academic Press, New York, NY.
HennessyE, GriffinEW, CunninghamC (2015) Astrocytes are primed by chronic neurodegeneration to produce exaggerated chemokine and cell infiltration responses to acute stimulation with the cytokines IL-1β and TNF-α. J Neurosci35, 8411–8422.
72.
WeiJ, WuF, HeA, ZengX, OuyangLS, LiuMS, ZhengHQ, LeiWL, WuZD, LvZY (2015) Microglia activation: One of the checkpoints in the CNS inflammation caused by Angiostrongylus cantonensis infection in rodent model. Parasitol Res114, 3247–3254.
73.
SutinenEM, PirttiläT, AndersonG, SalminenA, OjalaJO (2012) Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated Amyloid-β production in human neuron-like cells. J Neuroinflammation16, 199.
74.
SutinenEM, KorolainenMA, HäyrinenJ, AlafuzoffI, PetratosS, SalminemA, SoininenH, PirttiläT, OjalaO (2014) Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cells. Front Cell Neurosci8, 214.
75.
LalH, VermaSK, GoldenHB, FosterDM, SmithM, DostalDE (2008) Stretch-induced regulation of angiotensinogen gene expression in cardiac myocytes and fibroblasts: Opposing roles of JNK1/2 and p38 alpha MAP kinases. J Mol Cell Cardiol45, 770–778.
76.
MorganOO (1997) Cyclin-dependent kinase: Engines, clocks and microprocessors. Annu Rev Cell Dev Biol13, 261–291.
77.
AlvarezA, ToroR, CéceresA, MaccioniRB (1999) Inhibition of tau phosphorylation protein kinase cdk5 prevent beta-Amyloid induced neuronal death. FEBS Lett459, 421–426.
78.
SengupaA, WuO, Grundke-IqbalO, IqbalK, SinghT (1997) Alzheimer-like phosphorylation of human tau by cdk5. Moll Cell Biochem167, 99–105.
79.
JenkisSM, ZinnermanM, GamberC, JohnsonGVW (2000) Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J345, 263–270.
80.
EvansOB, RankKB, BhattachayraK, ThomsenOR, GurneyME, SharmaSK (2000) Tau phosphorylation at serine 396 and serina 404 by human recombinant Tau protein kinase II inhibits Tau's ability to promote microtubule assembly. J Biol Chem275, 24977–24938.
81.
ReynoldsCH, BettsJC, BlackstockWP, NebredaAR, AndersonBH (2000) Phosphorylation sites on tau identifies by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinase ERK, c-Jun N-terminal kinase and p38, and glycogen synthase kinase-3beta. J Neurochem74, 1587–1595.
82.
MastrangeloMA, BowersWJ (2008) Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer’s disease-related pathologies in male triple-transgenic mice. BMC Neurosci9, 81.
83.
Luna-MuñozJ, Chávez-MacíasL, García-SierraF, MenaR (2007) Earliest stages of Tau conformational changes are related to the appearance of a sequence of specific phospho-dependent Tau epitopes in Alzheimer’s disease. J Alzheimers Dis12, 365–375.
84.
MaurageCA, SergeantN, RuchouxMM, HauwJJ, DelacourteA (2001) Paradoxical phosphorylation of the serine 199 on tau protein from young individuals. Neuroreport12, 3177–3181.
85.
ZulianiG, RanziniM, GuerraG, RossiL, MuraniMR, ZurloA, VolpatoS, AttiAR, BléA, FellinR (2007) Plasma cytokines profile in older subjects with late onset Alzheimer’s disease or vascular dementia. J Psychiatr Res41, 686–693.
86.
OjalaJO, SutinenEM, SalminenA, PirttilaT (2008) Interleukin-18 increases expression of kinases involved in tau phosphorilatyon in SH-SY5Y neuroblastoma cells. J Neuroimmunol205, 86–93.
87.
UdanM L, AjitD, CrouseNR, NicholsMR (2008) Toll-like receptors 2 and 4 mediate Aβ(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem104, 524–533.
88.
KummerJA, BroekhuizenR, EverettH, AgostiniL, KuijkL, MartinonF, van BruggenR, TschoppJ (2007) Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem55, 443.
89.
MenuP, VinceJE (2011) The NLRP3 inflammasome in health and disease: The good, the bad and the ugly. Clin Exp Immunol166, 1–15.
90.
SandersMG, ParsonsMJ, HowardAG, LiuJ, FassioSR, MartínezJA, Bouchier-HayesL (2015) Single-cell imaging of inflammatory caspase dimerization reveals differential recruitment to inflammasomes. Cell Death Dis6, e1813.
91.
OguraY, SutterwalaFS, FlavellRA (2006) The inflammasome: First line of the immune response to cell stress. Cell126, 659–662.
92.
WalkerDG, LueLF, BeachTG (2001) Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging22, 957–966.
93.
GrellM (1995) Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J Inflammation47, 8–17.
94.
HalleA, HornungV, PetzoldGC, StewartCR, MonksBG, ReinheckelT, FitzgeraldKA, LatzE, MooreKJ, GolenbockDT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-β
. Nat Immunol9, 857–865.
95.
FariaMC, GoncalvesGS, RochaNP, MoraesEN, BicalhoMA, Gualberto CintraMT, Jardim de PaulaJ, José Ravic de MirandaLF, Clayton de Souza FerreiraA, TeixeiraAL, GomesKB, CarvalhoMD, SousaLP (2014) Increased plasma levels of BDNF and inflammatory markers in Alzheimer’s disease. J Psychiatr Res53, 166–172.
96.
BaudV, KarinM (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol11, 372–377.
97.
KawasakiH, OnukiR, SuyamaE, TairaK (2002) Identification of genes that function in the TNF-α-mediated apoptotic pathway using randomized hybrid ribozyme libraries. Nat Biotechnol20, 376–380.
98.
LourencoMV, ClarkeJR, FrozzaRL, BomfimTR, Forny-GermanoL, BatistaAF, SathlerLB, Brito-MoreiraJ, AmaralOB, SolvaCA, Freitas-CorreaL, Espírito-SantoS, Campello-CostaP, HouzelJC, KleinWL, HolscherC, CarvalheiraJB, SilvaAM, VellosoLA, MunozDP, FerreiraST, De FeliceFG (2013) TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer’s β-Amyloid oligomers in mice and monkeys. Cell Metab18, 831–843.
99.
MillerN, FengZ, EdensBM, YangB, ShiH, SzeCC, HongBT, SuSC, CantuJA, TopczewskiJ, CrawfordTO, KoCP, SummerCJ, MaL, MaYC (2015) Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy. J Neurosci35, 6038–6050.
100.
SunLH, BanT, LiuCD, ChenQX, WangX, YanML, HuXL, SuXL, BaoYN, SunLL, ZhaoLJ, PeiSC, JiangXM, ZongDK, AiJ (2015) Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 dowregulation. J Neurochem134, 1139–1151.
101.
DobarroM, GerenuG, RamírezMJ (2013) Propranolol reduces cognitive deficits, Amyloid and tau pathology in Alzheimer’s transgenic mice. Int J Neuropsychopharmacol16, 2245–2257.
BomfimTR, Forny-GermanoL, SathlerLB, Brito-MoreiraJ, HouzelJC, DeckerH, SilvermanMA, KaziH, MeloHM, McCleanPL, HolscherC, ArnoldSE, TalbotK, KleinWL, MunozDP, FerreiraST, De FeliceFG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Aβ oligomers. J Clin Invest122, 1339–1353.
104.
TamagnoE, ParolaM, BardiniP, PicciniA, BorghiR, GuglielmottoM, SantoroG, DavitA, DanniO, SmithMA, PerryG, TabatonM (2005)
β-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathway. J Neurochem92, 628–636.
105.
GregorMF, HotamisligilGS (2011) Inflammatory mechanism in obesity. Annu Rev Immunol29, 415–445.
106.
DaviesC, TournierC (2012) Exploring the function of the JNK (c-Jun N-terminal kinase) signaling pathway in the physiological and pathological processes to design novel therapeutic strategies. Biochem Soc Trans40, 85–89.
107.
EngströmW, WardA, MoorwoodK (2010) The role of scaffold proteins in JNK signaling. Cell Prolif43, 56–66.
108.
CoffeyET (2014) Nuclear and cytosolic JNK signalling in neurons. Nat Rev Neurosci15, 285–299.
109.
NorseenJ, HosookaT, HammarstedtA, YoreMM, KantS, AryalP, KiernanUA, PhillipsDA, MaruyamaH, KrausBJ, UshevaA, DavisRJ, SmithU, KahnBB (2012) Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. Mol Cell Biol.32, 2010–2019.
110.
HimesSR, SesterDP, RavasiT, CronauSL, SasmonoT, HumeDA (2006) The JNK are important for development and survival of macrophages. J Immunol176, 2219–2228.
SprowlesA, RobinsonD, WuYM, KungHJ, WisdomR (2005) c-Jun controls the efficiency of MAP kinase signaling by transcriptional repression of MAP kinase phosphatases. Exp Cell Res308, 459–468.
113.
HirosumiJ, TuncmanG, ChangLF, GorgunCZ, UysalKT, MaedaK, KarinM, HotamisligilGS (2002) A central role for JNK in obesity and insulin resistance. Nature429, 333–336.
114.
MoulinN, WidmannC (2004) Islet-brain (IB)/JNK-interacting proteins (JIPs): Future targets for the treatment of neurodegenerative diseases?Curr Neurovasc Res1, 111–127.
115.
HeasleyLE, HanSY (2006) JNK regulation of oncogenesis. Moll Cells21, 167–173.
116.
ZarubinT, HanJ (2005) Activation and signaling of the p38 MAP kinase pathway. Cell Res15, 11–18.
117.
AtzoriC, GhettiB, PivaR, SrinivasanAN, ZoloP, DelisleMB, MirraSS, MigheliA (2001) Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol60, 1190–1197.
118.
FerrerI, BlancoR, CarmonaM, PuigB (2001) Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM Kinase II) are differentially expressed in tau deposit in neurons and glial cells in tauopathies. J Neural Transm108, 1397–1415.
119.
CrossD, CulbertA, ChalmersKA, FacciL, SkaperSD, ReithAD (2001) Selective small molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death. J Neurochem77, 94–102.
120.
SavageMJ, LinYG, CiallellaJR, FloodDG, ScottRW (2002) Activation of c-Jun N-terminal kinase and p38 in Alzheimer’s disease model is associated with amyloid deposition. The J Neurosci22, 3376–3385.
121.
FerrerI, Gomez-IslaT, PuigB, FreixesM, RibéE, DalfóE, AvilaJ (2005) Current advances on different kinases involved in Tau phosphorylation, and implications in Alzheimer’s disease and tauopathies. Curr Alzheimer Res2, 3–18.
122.
TezelG, YangX, YangJ, WaxMB (2004) Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice. Brain Res996, 202–212.
123.
KimHS, KimEM, LeeJP, ParkCH, KimS, SeoJH, ChangKA, YuE, JeongSJ, ChongYH, SuhYH (2003) C-terminal fragments of Amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. FASEB J17, 1951–1953.
